Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemRelated Party TransactionsResults View source PDF

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-7.2%1-day move

₹1799.00

prior close

₹1688.70

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.2+0.3+0.6+0.5-7.2-7.9-8.5-6.9-7.9-7.1-5.2-2.2+2.0—

Up moveDown movePending

AI summary

Emcure Pharmaceuticals reported strong FY26 results with consolidated revenue crossing the US$ 1 billion milestone at Rs 9,204 Cr, up 16.6% YoY. Profit After Tax grew 33.1% to Rs 941 Cr, with adjusted PAT up 40.9% to Rs 1,008 Cr. International business showed robust growth of 22.2% to Rs 5,177 Cr, while domestic business grew 10% to Rs 4,027 Cr. EBITDA margins expanded to 19.4% from 18.6% YoY. The company completed the Zuventus minority buyout and made bolt-on acquisitions in UK and Canada during the year.

Likely market impact

Strong results with double-digit revenue growth and PAT growth exceeding 25%, indicating above-industry performance. EBITDA margin expansion signals improving operational efficiency, which is positive for shareholders.